U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)
PRINCETON, N.J.--(BUSINESS WIRE) December 15, 2021 -- Bristol Myers Squibb (NYSE:BMY) today announced that Orencia (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis, or prevention, of acute graft... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 15, 2021 Category: Drugs & Pharmacology Source Type: news
Glucarpidase Approval in Europe for Methotrexate Toxicity in View Glucarpidase Approval in Europe for Methotrexate Toxicity in View
Glucarpidase, already approved in the US, has been shown to reduce methotrexate concentrations by up to 99% within 15 minutes of administration.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Methotrexate toxicity from unintentional dosing errors: calls to a poison center and death descriptions - Thompson JA, Love JS, Hendrickson RG.
BACKGROUND: Methotrexate is a folate analog prescribed for varying disease with weekly administration as opposed to daily. Dosing errors can prove clinically significant and sometimes fatal. METHODS: We performed a retrospective poison center revie... (Source: SafetyLit)
Source: SafetyLit - November 16, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Psoriatic Arthritis Management: From Intramuscular Gold to Biologics Psoriatic Arthritis Management: From Intramuscular Gold to Biologics
Phillip J. Mease, MD, reflects on the development of therapeutics for psoriatic arthritis, from intramuscular gold and oral methotrexate in former decades, to the recent use of biologics.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2021 Category: Consumer Health News Tags: Rheumatology MDAngle Source Type: news
Risk for VTE in RA May Be Higher With MTX vs Hydroxychloroquine Risk for VTE in RA May Be Higher With MTX vs Hydroxychloroquine
The significance of higher risk for VTE seen among patients with RA who took methotrexate compared with hydroxychloroquine is unclear without researching the relationships between the drugs and VTE.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - November 4, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news
Methotrexate Cannot Maintain TNFi-Induced Remission in pSpA Methotrexate Cannot Maintain TNFi-Induced Remission in pSpA
Is the addition of methotrexate an effective step-down strategy in patients who achieved clinical remission with TNF inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [ACR] 20/50/70)a a...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Mayo Clinic Q and A: Treating a rare skin disorder known as morphea
DEAR MAYO CLINIC: About six months ago, a large, white dent appeared on my left buttock. I went to a dermatologist who performed a biopsy. I was diagnosed with morphea and prescribed methotrexate. The doctor said the condition is not systemic, but that the drug could prevent future skin lesions and possibly cure the morphea. Can you share more about the condition, and the risks and benefits of the treatment? ANSWER: Morphea, which is a rare skin… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 30, 2021 Category: Databases & Libraries Source Type: news
Five Biologics Perform Strongly in Children With Psoriasis Five Biologics Perform Strongly in Children With Psoriasis
Biologic therapy for children with psoriasis was associated with a significantly increased likelihood of achieving PASI 75 or PASI 100, compared with placebo or methotrexate.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 28, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
Does Methotrexate Influence Covid-19 Infection? Does Methotrexate Influence Covid-19 Infection?
Might treatment with methotrexate help lower the risk for developing COVID-19? A new study examines the possible protective effects of this drug.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Patients on Methotrexate Show T-Cell Response to Pfizer Vaccine Patients on Methotrexate Show T-Cell Response to Pfizer Vaccine
Despite poor antibody response to the mRNA COVID-19 vaccine, cellular immunity was generated in patients taking methotrexate, new research shows.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - July 12, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
